Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era

References

• Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105:1684.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
   Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Merli F, Luminari S, Rossi G, et al. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leuk Lymphoma. 2012;53:581–588.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Flinn IW, Spigel DR, et al. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma Leuk. 2010;10:44–50.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. JCO. 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03–6B study): a randomised phase 3 trial. Lancet Oncol. 2013;14:525–533.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381:1817–1826.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Lamb MR, et al. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial. Clin Lymphoma. 2003;4:36–42.
   PubMedGoogle Scholar
• Fina M, Tani M, Stefoni V, et al. VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. Leuk Lymphoma. 2007;48:2167–2171.
   PubMed Web of Science ®Google Scholar
• Oki Y, Ewer MS, Lenihan DJ, et al. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015;15:152–158.
   PubMed Web of Science ®Google Scholar
• Hagemeister F, Rodriguez MA, Deitcher SR, et al. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®)) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol. 2013;162:631–638.
   PubMed Web of Science ®Google Scholar
• Corazzelli G, Frigeri F, Arcamone M, et al. Biweekly rituximab, cyclophosphamide, vincristine, non‐pegylated liposome‐encapsulated doxorubicin and prednisone (R‐COMP‐14) in elderly patients with poor‐risk diffuse large B‐cell lymphoma and moderate to high ‘life threat’ impact cardiopathy. Br J Haematol. 2011;154:579–589.
   PubMed Web of Science ®Google Scholar
• Aviles A, Nambo MJ, Castaneda C, et al. Rituximab and escalated chemotherapy in elderly patients with aggressive diffuse large-cell lymphoma: a controlled clinical trial. Cancer Biother Radiopharm. 2007;22:194–199.
   PubMed Web of Science ®Google Scholar
• Hara T, Tsurumi H, Goto N, et al. Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. J Cancer Res Clin Oncol. 2010;136:65–70.
   PubMed Web of Science ®Google Scholar
• Gimeno E, Sánchez-González B, Álvarez-Larrán A, et al. Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma. Leuk Res. 2011;35:358–362.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Poeschel V, Zeynalova S, et al. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group. J Clin Oncol. 2014;2013.54. 6861
   Google Scholar
• Murawski N, Pfreundschuh M, Zeynalova S, et al. Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann Oncol. 2014;25:1800–1806.
   PubMed Web of Science ®Google Scholar
• Jung SH, Lee JJ, Kim WS, et al. Weekly rituximab consolidation following four cycles of R‐CHOP induction chemotherapy in very elderly patients with diffuse large B‐cell lymphoma: consortium for improving survival of lymphoma study (CISL). Eur J Haematol. 2015;94:504–510.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Tilly H, Gomes da Silva M, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;22:2473–2481.
   Google Scholar
• Zinzani PL, Rossi G, Franceschetti S, et al. Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res. 2010;16:3998–4004.
   PubMed Web of Science ®Google Scholar
• Zinzani P, Tani M, Fanti S, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol. 2008;19:769–773.
   PubMed Web of Science ®Google Scholar
• Kraeber-Bodere F, Pallardy A, Maisonneuve H, et al. Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. Lancet Haematol. 2017;4:e35–e45.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Rodriguez MA, Noy A, et al. Final results of a phase II study of sequential R-CHOP and Yttrium-90 ibritumomab tiuxetan (RIT) for elderly high risk patients with untreated diffuse large B-cell lymphoma (DLBCL). Blood. 2010;116:1793.
   Web of Science ®Google Scholar
• Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35:3529–3537.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Chiappella A, Franceschetti S, et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol. 2014;15:730–737.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Internal PLoS Med. 2009;151:W-65-W-94.
   Google Scholar
• Jaeger U, Trneny M, Melzer H, et al. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. Haematologica. 2015;100:955–963.
   PubMed Web of Science ®Google Scholar
• Weidmann E, Neumann A, Fauth F, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011;22:1839–1844.
   PubMed Web of Science ®Google Scholar
• Spina M, Balzarotti M, Uziel L, et al. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist. 2012;17:838–846.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Bologna S, Delwail V, et al. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017;4:e46–e55.
   PubMed Web of Science ®Google Scholar
• Ishii K, Urase F, Nagare Y, et al. VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience. Arch Gerontol Geriatr. 2010;51:209–215.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12:460–468.
   PubMed Web of Science ®Google Scholar
• Musolino A, Boggiani D, Panebianco M, et al. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Cancer. 2011;117:964–973.
   PubMed Web of Science ®Google Scholar
• Fields PA, Townsend W, Webb A, et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. JCO. 2013;32:282–287.
   PubMed Web of Science ®Google Scholar
• Rigacci L, Nassi L, Alterini R, et al. Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study. Acta Haematol. 2006;115:22–27.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. JCO. 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Zaja F, Tomadini V, Zaccaria A, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006;47:2174–2180.
   PubMed Web of Science ®Google Scholar
• Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal doxorubicin (Myocet™) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol. 2010;21:1492–1499.
   PubMed Web of Science ®Google Scholar
• Dell'olio M, Potito scalzulli R, Sanpaolo G, et al. Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2011;52:1222–1229.
   PubMed Web of Science ®Google Scholar
• Kasahara S, Hara T, Tsurumi H, et al. Phase II study of the tetrahydropyranyl adriamycin–cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;52:629–634.
   PubMed Web of Science ®Google Scholar
• Shin H-J, Chung JS, Song M-K, et al. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma. Cancer Chemother Pharmacol. 2012;69:1165–1172.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685–2693.
   PubMed Web of Science ®Google Scholar
• Purroy N, López A, Vallespi T, et al. Dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor risk large B-cell lymphoma. A phase 2 study conducted by the Spanish PETHEMA Group. Blood. 2009;114:2701.
   Web of Science ®Google Scholar
• Wilson WH, Pitcher BN, Hsi ED, et al. Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/Alliance 50303. Blood. 2016;128:469.
   Web of Science ®Google Scholar
• Nowakowski GS, Chiappella A, Witzig TE, et al. ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future Oncol. 2016;12:1553–1563.
   PubMed Web of Science ®Google Scholar
• Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol. 1999;26:58–65.
   PubMed Web of Science ®Google Scholar
• Tomblyn M. Radioimmunotherapy for B-cell non-Hodgkin lymphomas. Cancer Control. 2012;19:196–203.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Broccoli A, Stefoni V, et al. Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. Cancer. 2010;116:5667–5675.
   PubMed Web of Science ®Google Scholar
• Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. JCO. 2014;32:2595–2603.
   PubMed Web of Science ®Google Scholar
• Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol/Hematol. 2000;35:181–200.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Barca E, Canales MA, Salar A, et al. Long-term follow-up of a Phase II trial of six cycles of dose-dense R-CHOP-14 for first-line treatment of diffuse large B-cell lymphoma in young and elderly patients. Acta Haematol. 2016;136(2):76–84.
   PubMed Web of Science ®Google Scholar
• Purroy N, Bergua J, Gallur L, et al. A phase II study conducted by the Spanish PETHEMA Group. Long‐term follow‐up of dose‐adjusted EPOCH plus rituximab (DA‐EPOCH‐R) in untreated patients with poor prognosis large B‐cell lymphoma. Brit J Hematol. 2015;169(2):188–198.
   PubMed Web of Science ®Google Scholar